Zoledronic Acid as Adjunct to Androgen Deprivation Therapy Reduces Bone Loss in Men With Prostate Cancer

The use of bisphosphonates in cancer treatment

“…69,70 In four randomized controlled trials in men with nonmetastatic prostate cancer receiving ADT (n = 106, 120, 200, and 215, respectively), zoledronic acid (4 mg IV every 3 months for 1 year) consistently prevented BMD loss at the lumbar spine and total hip, and was significantly superior to placebo (P ≤ 0.001 for all). [71][72][73][74] In addition, in a small study in men undergoing ADT (n = 40), a single dose of zoledronic acid (4 mg) appeared sufficient to prevent BMD loss versus placebo at 12 months (P ≤ 0.004 at all sites). 75…”

“…Pamidronate (60 mg every 3 months) significantly prevented ADT‐associated BMD loss versus placebo during a small 1‐year trial ( n = 47), 68 and oral alendronate (70 mg once weekly) has demonstrated similar efficacy in two separate trials in men receiving ADT for nonmetastatic prostate cancer ( n = 47 and 112) 69,70 . In four randomized controlled trials in men with nonmetastatic prostate cancer receiving ADT ( n = 106, 120, 200, and 215, respectively), zoledronic acid (4 mg IV every 3 months for 1 year) consistently prevented BMD loss at the lumbar spine and total hip, and was significantly superior to placebo ( P ≤ 0.001 for all) 71–74 . In addition, in a small study in men undergoing ADT ( n = 40), a single dose of zoledronic acid (4 mg) appeared sufficient to prevent BMD loss versus placebo at 12 months ( P ≤ 0.004 at all sites) 75 …”

New results from the use of bisphosphonates in cancer patients

“…Pamidronate (60 mg every 3 months) significantly prevented ADT-associated BMD loss compared with placebo during a small 1-year trial (n ¼ 47) [38], and oral alendronate (70 mg once weekly) has demonstrated similar efficacy in two separate trials in men receiving ADT for nonmetastatic prostate cancer (n ¼ 47 and n ¼ 112) [39,40]. In four randomized controlled trials in men with nonmetastatic prostate cancer receiving ADT (n ¼ 106, 120, 200 and 215, Use of bisphosphonates in cancer patients Coleman and Gnant 215 respectively), zoledronic acid (4 mg intravenously every 3 months for 1 year) consistently prevented BMD loss at the lumbar spine and total hip, and was significantly superior to placebo (P 0.001 for all) [41][42][43][44]. Additionally, in a small study in men undergoing ADT (n ¼ 40), a single dose of zoledronic acid (4 mg) appeared sufficient to prevent BMD loss compared with placebo at 12 months (P 0.004 at all sites) [45].…”